The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Alzheimer's Disease Drug-Global Market Insights and Sales Trends 2025
Synopsis
Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia.
The global Alzheimer's Disease Drug market size is expected to reach US$ 4020.5 million by 2029, growing at a CAGR of 1.5% from 2023 to 2029. The market is mainly driven by the significant applications of Alzheimer's Disease Drug in various end use industries. The expanding demands from the Early to Moderate Stages and Moderate to Severe Stages, are propelling Alzheimer's Disease Drug market. Donepezil, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Memantine segment is estimated at % CAGR for the next seven-year period.
The major players in global Alzheimer’s Disease Drug market include Allergan, Eisai, Novartis, Daiichi Sankyo, Merz Pharma, Pfizer, Johnson & Johnson, Lundbeck, etc. The top 3 players hold over 60% of global shares. Europe and North America are main markets, they occupy over 70% of the global market. Memantine and Donepezil are the main types, with a share about 70%. Early to Moderate Stages is the key application, which covers over 55% shares.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Alzheimer's Disease Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Alzheimer's Disease Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Alzheimer's Disease Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Alzheimer's Disease Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Alzheimer's Disease Drug covered in this report include Allergan, Eisai, Novartis, Daiichi Sankyo, Merz Pharma, Pfizer, Johnson & Johnson and Lundbeck, etc.
The global Alzheimer's Disease Drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Allergan
Eisai
Novartis
Daiichi Sankyo
Merz Pharma
Pfizer
Johnson & Johnson
Lundbeck
Global Alzheimer's Disease Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Alzheimer's Disease Drug market, Segment by Type:
Donepezil
Memantine
Rivastigmine
Others
Global Alzheimer's Disease Drug market, by Application
Early to Moderate Stages
Moderate to Severe Stages
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Alzheimer's Disease Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Alzheimer's Disease Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia.
The global Alzheimer's Disease Drug market size is expected to reach US$ 4020.5 million by 2029, growing at a CAGR of 1.5% from 2023 to 2029. The market is mainly driven by the significant applications of Alzheimer's Disease Drug in various end use industries. The expanding demands from the Early to Moderate Stages and Moderate to Severe Stages, are propelling Alzheimer's Disease Drug market. Donepezil, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Memantine segment is estimated at % CAGR for the next seven-year period.
The major players in global Alzheimer’s Disease Drug market include Allergan, Eisai, Novartis, Daiichi Sankyo, Merz Pharma, Pfizer, Johnson & Johnson, Lundbeck, etc. The top 3 players hold over 60% of global shares. Europe and North America are main markets, they occupy over 70% of the global market. Memantine and Donepezil are the main types, with a share about 70%. Early to Moderate Stages is the key application, which covers over 55% shares.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Alzheimer's Disease Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Alzheimer's Disease Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Alzheimer's Disease Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Alzheimer's Disease Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Alzheimer's Disease Drug covered in this report include Allergan, Eisai, Novartis, Daiichi Sankyo, Merz Pharma, Pfizer, Johnson & Johnson and Lundbeck, etc.
The global Alzheimer's Disease Drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Allergan
Eisai
Novartis
Daiichi Sankyo
Merz Pharma
Pfizer
Johnson & Johnson
Lundbeck
Global Alzheimer's Disease Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Alzheimer's Disease Drug market, Segment by Type:
Donepezil
Memantine
Rivastigmine
Others
Global Alzheimer's Disease Drug market, by Application
Early to Moderate Stages
Moderate to Severe Stages
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Alzheimer's Disease Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Alzheimer's Disease Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Alzheimer's Disease Drug Market Overview
1.1 Alzheimer's Disease Drug Product Overview
1.2 Alzheimer's Disease Drug Market Segment by Type
1.2.1 Donepezil
1.2.2 Memantine
1.2.3 Rivastigmine
1.2.4 Others
1.3 Global Alzheimer's Disease Drug Market Size by Type
1.3.1 Global Alzheimer's Disease Drug Market Size Overview by Type (2018-2029)
1.3.2 Global Alzheimer's Disease Drug Historic Market Size Review by Type (2018-2023)
1.3.3 Global Alzheimer's Disease Drug Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Alzheimer's Disease Drug Sales Breakdown by Type (2018-2023)
1.4.2 Europe Alzheimer's Disease Drug Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Alzheimer's Disease Drug Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Alzheimer's Disease Drug Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Alzheimer's Disease Drug Sales Breakdown by Type (2018-2023)
2 Global Alzheimer's Disease Drug Market Competition by Company
2.1 Global Top Players by Alzheimer's Disease Drug Sales (2018-2023)
2.2 Global Top Players by Alzheimer's Disease Drug Revenue (2018-2023)
2.3 Global Top Players by Alzheimer's Disease Drug Price (2018-2023)
2.4 Global Top Manufacturers Alzheimer's Disease Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Alzheimer's Disease Drug Market Competitive Situation and Trends
2.5.1 Alzheimer's Disease Drug Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Alzheimer's Disease Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Alzheimer's Disease Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Alzheimer's Disease Drug Market
2.8 Key Manufacturers Alzheimer's Disease Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Alzheimer's Disease Drug Status and Outlook by Region
3.1 Global Alzheimer's Disease Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Alzheimer's Disease Drug Historic Market Size by Region
3.2.1 Global Alzheimer's Disease Drug Sales in Volume by Region (2018-2023)
3.2.2 Global Alzheimer's Disease Drug Sales in Value by Region (2018-2023)
3.2.3 Global Alzheimer's Disease Drug Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Alzheimer's Disease Drug Forecasted Market Size by Region
3.3.1 Global Alzheimer's Disease Drug Sales in Volume by Region (2024-2029)
3.3.2 Global Alzheimer's Disease Drug Sales in Value by Region (2024-2029)
3.3.3 Global Alzheimer's Disease Drug Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Alzheimer's Disease Drug by Application
4.1 Alzheimer's Disease Drug Market Segment by Application
4.1.1 Early to Moderate Stages
4.1.2 Moderate to Severe Stages
4.2 Global Alzheimer's Disease Drug Market Size by Application
4.2.1 Global Alzheimer's Disease Drug Market Size Overview by Application (2018-2029)
4.2.2 Global Alzheimer's Disease Drug Historic Market Size Review by Application (2018-2023)
4.2.3 Global Alzheimer's Disease Drug Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Alzheimer's Disease Drug Sales Breakdown by Application (2018-2023)
4.3.2 Europe Alzheimer's Disease Drug Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Alzheimer's Disease Drug Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Alzheimer's Disease Drug Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Alzheimer's Disease Drug Sales Breakdown by Application (2018-2023)
5 North America Alzheimer's Disease Drug by Country
5.1 North America Alzheimer's Disease Drug Historic Market Size by Country
5.1.1 North America Alzheimer's Disease Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Alzheimer's Disease Drug Sales in Volume by Country (2018-2023)
5.1.3 North America Alzheimer's Disease Drug Sales in Value by Country (2018-2023)
5.2 North America Alzheimer's Disease Drug Forecasted Market Size by Country
5.2.1 North America Alzheimer's Disease Drug Sales in Volume by Country (2024-2029)
5.2.2 North America Alzheimer's Disease Drug Sales in Value by Country (2024-2029)
6 Europe Alzheimer's Disease Drug by Country
6.1 Europe Alzheimer's Disease Drug Historic Market Size by Country
6.1.1 Europe Alzheimer's Disease Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Alzheimer's Disease Drug Sales in Volume by Country (2018-2023)
6.1.3 Europe Alzheimer's Disease Drug Sales in Value by Country (2018-2023)
6.2 Europe Alzheimer's Disease Drug Forecasted Market Size by Country
6.2.1 Europe Alzheimer's Disease Drug Sales in Volume by Country (2024-2029)
6.2.2 Europe Alzheimer's Disease Drug Sales in Value by Country (2024-2029)
7 Asia-Pacific Alzheimer's Disease Drug by Region
7.1 Asia-Pacific Alzheimer's Disease Drug Historic Market Size by Region
7.1.1 Asia-Pacific Alzheimer's Disease Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Alzheimer's Disease Drug Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Alzheimer's Disease Drug Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Alzheimer's Disease Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Alzheimer's Disease Drug Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Alzheimer's Disease Drug Sales in Value by Region (2024-2029)
8 Latin America Alzheimer's Disease Drug by Country
8.1 Latin America Alzheimer's Disease Drug Historic Market Size by Country
8.1.1 Latin America Alzheimer's Disease Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Alzheimer's Disease Drug Sales in Volume by Country (2018-2023)
8.1.3 Latin America Alzheimer's Disease Drug Sales in Value by Country (2018-2023)
8.2 Latin America Alzheimer's Disease Drug Forecasted Market Size by Country
8.2.1 Latin America Alzheimer's Disease Drug Sales in Volume by Country (2024-2029)
8.2.2 Latin America Alzheimer's Disease Drug Sales in Value by Country (2024-2029)
9 Middle East and Africa Alzheimer's Disease Drug by Country
9.1 Middle East and Africa Alzheimer's Disease Drug Historic Market Size by Country
9.1.1 Middle East and Africa Alzheimer's Disease Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Alzheimer's Disease Drug Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Alzheimer's Disease Drug Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Alzheimer's Disease Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Alzheimer's Disease Drug Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Alzheimer's Disease Drug Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Allergan
10.1.1 Allergan Company Information
10.1.2 Allergan Introduction and Business Overview
10.1.3 Allergan Alzheimer's Disease Drug Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Allergan Alzheimer's Disease Drug Products Offered
10.1.5 Allergan Recent Development
10.2 Eisai
10.2.1 Eisai Company Information
10.2.2 Eisai Introduction and Business Overview
10.2.3 Eisai Alzheimer's Disease Drug Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Eisai Alzheimer's Disease Drug Products Offered
10.2.5 Eisai Recent Development
10.3 Novartis
10.3.1 Novartis Company Information
10.3.2 Novartis Introduction and Business Overview
10.3.3 Novartis Alzheimer's Disease Drug Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Novartis Alzheimer's Disease Drug Products Offered
10.3.5 Novartis Recent Development
10.4 Daiichi Sankyo
10.4.1 Daiichi Sankyo Company Information
10.4.2 Daiichi Sankyo Introduction and Business Overview
10.4.3 Daiichi Sankyo Alzheimer's Disease Drug Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Daiichi Sankyo Alzheimer's Disease Drug Products Offered
10.4.5 Daiichi Sankyo Recent Development
10.5 Merz Pharma
10.5.1 Merz Pharma Company Information
10.5.2 Merz Pharma Introduction and Business Overview
10.5.3 Merz Pharma Alzheimer's Disease Drug Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Merz Pharma Alzheimer's Disease Drug Products Offered
10.5.5 Merz Pharma Recent Development
10.6 Pfizer
10.6.1 Pfizer Company Information
10.6.2 Pfizer Introduction and Business Overview
10.6.3 Pfizer Alzheimer's Disease Drug Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Pfizer Alzheimer's Disease Drug Products Offered
10.6.5 Pfizer Recent Development
10.7 Johnson & Johnson
10.7.1 Johnson & Johnson Company Information
10.7.2 Johnson & Johnson Introduction and Business Overview
10.7.3 Johnson & Johnson Alzheimer's Disease Drug Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Johnson & Johnson Alzheimer's Disease Drug Products Offered
10.7.5 Johnson & Johnson Recent Development
10.8 Lundbeck
10.8.1 Lundbeck Company Information
10.8.2 Lundbeck Introduction and Business Overview
10.8.3 Lundbeck Alzheimer's Disease Drug Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Lundbeck Alzheimer's Disease Drug Products Offered
10.8.5 Lundbeck Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Alzheimer's Disease Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Alzheimer's Disease Drug Industrial Chain Analysis
11.4 Alzheimer's Disease Drug Market Dynamics
11.4.1 Alzheimer's Disease Drug Industry Trends
11.4.2 Alzheimer's Disease Drug Market Drivers
11.4.3 Alzheimer's Disease Drug Market Challenges
11.4.4 Alzheimer's Disease Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Alzheimer's Disease Drug Distributors
12.3 Alzheimer's Disease Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
